The US asthma spacers market was valued at US$ 472.92 million in 2019 and is projected to reach US$ 702.27 million by 2027; it is expected to grow at a CAGR of 5.3% during 2020-2027.
The market growth is mainly attributed to factors such as increasing prevalence of respiratory conditions and growing awareness regarding benefits conferred by spacers. However, increased risk of adverse effects due to unlicensed prescriptions restrains the growth of the market.
Asthma spacers are tube-like devices that are attached to inhalers for better administration of doses. Generally, spacers help administer the medication directly to lungs, thereby reducing the chances of side effects that may occur when the drug comes in contact with mouth and throat.
The COVID-19 pandemic has affected on the US asthma spacers market. It has disrupted the supply chain operations in the country. However, the healthcare authorities and government organizations in the US are focusing on spreading awareness about COVID-19 among asthmatic patients as they are highly vulnerable to other lung infections. Such awareness programs are likely to have positive impact on the adoption of asthma spacers due to precautionary measures, which will eventually drive the market up to certain extent.
Based on product, the asthma spacers market is segmented into aerochamber, optichamber, volumatic, and inspirease. The aerochamber segment held the largest share of the market in 2019; it is further is anticipated to register the highest CAGR in the market during the forecast period. Based on distribution channel, the asthma spacers market is segmented into retail pharmacy, hospital pharmacy, and E-commerce. The retail pharmacy segment held the largest share of the market in 2019; however, E-commerce segment estimated to register the highest CAGR in the market during the forecast period.
The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Asthma and Allergy Foundation of America are among the major primary and secondary sources referred to while preparing the US asthma spacers market report.
Reasons to Buy
The market growth is mainly attributed to factors such as increasing prevalence of respiratory conditions and growing awareness regarding benefits conferred by spacers. However, increased risk of adverse effects due to unlicensed prescriptions restrains the growth of the market.
Asthma spacers are tube-like devices that are attached to inhalers for better administration of doses. Generally, spacers help administer the medication directly to lungs, thereby reducing the chances of side effects that may occur when the drug comes in contact with mouth and throat.
The COVID-19 pandemic has affected on the US asthma spacers market. It has disrupted the supply chain operations in the country. However, the healthcare authorities and government organizations in the US are focusing on spreading awareness about COVID-19 among asthmatic patients as they are highly vulnerable to other lung infections. Such awareness programs are likely to have positive impact on the adoption of asthma spacers due to precautionary measures, which will eventually drive the market up to certain extent.
Based on product, the asthma spacers market is segmented into aerochamber, optichamber, volumatic, and inspirease. The aerochamber segment held the largest share of the market in 2019; it is further is anticipated to register the highest CAGR in the market during the forecast period. Based on distribution channel, the asthma spacers market is segmented into retail pharmacy, hospital pharmacy, and E-commerce. The retail pharmacy segment held the largest share of the market in 2019; however, E-commerce segment estimated to register the highest CAGR in the market during the forecast period.
The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Asthma and Allergy Foundation of America are among the major primary and secondary sources referred to while preparing the US asthma spacers market report.
Reasons to Buy
- Saves and reduces time required for carrying out entry-level research by identifying the growth, size, leading players, and segments in the US asthma spacers market
- Highlights key business priorities to assist companies in order to realign their business strategies
- Highlights key findings and recommendations of crucial progressive industry trends in the US asthma spacers market, thereby allowing players across the value chain to develop effective long-term strategies
- Develops/modifies business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinizes in-depth US market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhances the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. US Asthma Spacers Market - Market Landscape
5. Asthma Spacers Market - Key Market Dynamics
6. Asthma Spacers Market- US Analysis
7. Asthma Spacers Market Analysis - By Product
8. Asthma Spacers Market Analysis - By Distribution Channel
9. Impact of COVID-19 Pandemic on US Asthma Spacers Market
10. US Asthma Spacers Market -Industry Landscape
11. Company Profiles
12. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cipla Inc.
- PARI GmbH
- Koninklijke Philips N.V.
- Lupin
- HAAG-STREIT GROUP
- Laboratoire ProtecSom
- Monaghan Medical Corporation
- Koo Medical Equipment
- Agaplastic
- Teleflex Incorporated
